Zobrazeno 1 - 10
of 176
pro vyhledávání: '"Labrenz, J."'
Autor:
Harris DMM; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany; Institute for Human Nutrition and Food Science, Division Nutriinformatics, Kiel University, Kiel, Germany., Szymczak S; Institute of Medical Biometry and Statistics, University of Lübeck, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany., Schuchardt S; Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hanover, Germany., Labrenz J; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Tran F; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Internal Medicine I, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Welz L; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany; Institute for Human Nutrition and Food Science, Division Nutriinformatics, Kiel University, Kiel, Germany., Graßhoff H; Department of Rheumatology University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany., Zirpel H; Comprehensive Center for Inflammation Medicine, University Medical Center Schleswig-Holstein, Lübeck, Germany., Sümbül M; Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Oumari M; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Engelbogen N; Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Junker R; Institute of Clinical Chemistry, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Conrad C; Department of Internal Medicine I, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Thaçi D; Comprehensive Center for Inflammation Medicine, University Medical Center Schleswig-Holstein, Lübeck, Germany., Frey N; Department of Medicine III: Cardiology, Angiology, and Pneumology, Heidelberg University, Heidelberg, Germany., Franke A; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Weidinger S; Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Hoyer B; Department of Internal Medicine I, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Rosenstiel P; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Waschina S; Institute for Human Nutrition and Food Science, Division Nutriinformatics, Kiel University, Kiel, Germany., Schreiber S; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Internal Medicine I, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany., Aden K; Institute of Clinical Molecular Biology, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany; Department of Internal Medicine I, Kiel University and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. Electronic address: k.aden@ikmb.uni-kiel.de.
Publikováno v:
EBioMedicine [EBioMedicine] 2024 Apr; Vol. 102, pp. 105056. Date of Electronic Publication: 2024 Mar 11.
Autor:
Bernard, C., Blum, T., De, A., DeGrand, T., DeTar, C., Gottlieb, Steven, Heller, Urs M., Hetrick, J., Ishizuka, N., Labrenz, J., Rummukainen, K., Soni, A., Sugar, R., Toussaint, D., Wingate, M.
Publikováno v:
Nucl.Phys.Proc.Suppl.47:459-462,1996
Results for $f_B$, $f_{B_s}$, $f_D$, $f_{D_s}$, and their ratios are presented. High statistics quenched runs at $\beta=5.7$, $5.85$, $6.0$, and $6.3$, plus a run still in progress at $\beta=6.52$ make possible a preliminary extrapolation to the cont
Externí odkaz:
http://arxiv.org/abs/hep-lat/9509045
Autor:
The MILC Collaboration, Bernard, C., Blum, T., De, A., DeGrand, T., DeTar, C., Gottlieb, Steven, Heller, Urs M., Ishizuka, N., Kärkkäinen, L., Labrenz, J., Rummukainen, K., Soni, A., Sugar, R., Toussaint, D.
Preliminary results from the MILC collaboration for $f_B$, $f_{B_s}$, $f_D$, $f_{D_s}$ and their ratios are presented. We compute in the quenched approximation at $\beta=6.3$, 6.0 and 5.7 with Wilson light quarks and static and Wilson heavy quarks. W
Externí odkaz:
http://arxiv.org/abs/hep-ph/9503336
Autor:
Bernard, C., Blum, T., De, A., DeGrand, T., DeTar, C., Gottlieb, Steven, Heller, U. M., Ishizuka, N., Kärkkäinen, L., Labrenz, J., Soni, A., Sugar, R., Toussaint, D.
Publikováno v:
Nucl.Phys.Proc.Suppl.42:388-390,1995
Preliminary results from the MILC collaboration for $f_B$, $f_{B_s}$, $f_D$, $f_{D_s}$ and their ratios are presented. We compute in the quenched approximation at $\beta=6.3$, 6.0 and 5.7 with Wilson light quarks and static and Wilson heavy quarks. W
Externí odkaz:
http://arxiv.org/abs/hep-lat/9411080
Autor:
Lonsdorf AS; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany. anke.lonsdorf@med.uni-heidelberg.de., Edelmann D; German Cancer Research Center, Heidelberg, Germany; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany., Albrecht T; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Brobeil A; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Tissue Bank of the National Center for Tumor Diseases, Heidelberg, Germany ., Labrenz J; German Cancer Research Center, Heidelberg, Germany; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany., Johanning M; German Cancer Research Center, Heidelberg, Germany; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany., Schlenk RF; German Cancer Research Center, Heidelberg, Germany; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital, Heidelberg, Germany., Goeppert B; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany; Institute of Pathology and Neuropathology, RKH Klinikum Ludwigsburg, Germany., Enk AH; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany., Toberer F; Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.
Publikováno v:
Acta dermato-venereologica [Acta Derm Venereol] 2024 Feb 07; Vol. 104, pp. adv13381. Date of Electronic Publication: 2024 Feb 07.
Autor:
Heitmann JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Schlenk RF; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany., Dörfel D; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Department of Hematology, Oncology and Immunology, KRH Klinikum Siloah, Hannover, Germany., Kayser S; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Medical Clinic and Policlinic 1, Hematology, Cellular Therapy and Hemostaseology, University of Leipzig Medical Center, Leipzig, Germany.; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany., Döhner K; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Heuser M; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Thol F; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Kapp-Schwoerer S; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Labrenz J; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany., Edelmann D; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center (DKFZ) and Heidelberg University Hospital, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Märklin M; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany., Vogel W; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Bethge W; Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany., Walz JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany.; Department of Peptide-Based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Große-Hovest L; Synimmune GmbH, Tübingen, Germany., Steiner M; Synimmune GmbH, Tübingen, Germany., Jung G; Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, University of Tübingen, Tübingen, Germany. helmut.salih@med.uni-tuebingen.de.; Cluster of Excellence iFIT (EXC2180) 'Image-Guided and Functionally Instructed Tumor Therapies', University of Tübingen, Tübingen, Germany. helmut.salih@med.uni-tuebingen.de.
Publikováno v:
Journal of hematology & oncology [J Hematol Oncol] 2023 Aug 17; Vol. 16 (1), pp. 96. Date of Electronic Publication: 2023 Aug 17.
Autor:
Lanz, LM, Edelmann, D, Benner, A, Schäkel, U, Klose, C, Labrenz, J, Müller-Tidow, C, Schlenk, RF
Publikováno v:
66. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS), 12. Jahreskongress der Technologie-und Methodenplattform für die vernetzte medizinische Forschung e.V. (TMF); 20210926-20210930; sine loco [digital]; DOCAbstr. 114 /20210924/
Introduction: Response rate in r/r AML heavily depends on already known molecular and clinical data ranging from below 10% in patients with complex karyotypes and increasing to at least 80% in patients with CEBPA-biallelic mutations. Thus, adjustment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d74966a0a7a9d4aaee32f6ad6b844c7d
Publikováno v:
66. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e. V. (GMDS), 12. Jahreskongress der Technologie-und Methodenplattform für die vernetzte medizinische Forschung e.V. (TMF); 20210926-20210930; sine loco [digital]; DOCAbstr. 112 /20210924/
Introduction: Dose-finding phase I trials aim to determine the recommended phase II dose (RP2D) for further phase II drug development. One way to define the RP2D is to determine the maximum tolerated dose (MTD) which is based on dose-limiting toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48705c5b0821eff2818d877764005f78
Autor:
Le HD; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Pflaum T; Department of Pathology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Labrenz J; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Sari S; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Bretschneider F; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Tran F; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Lassen A; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Nikolaus S; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Szymczak S; Institute for Medical Biometry and Statistics, University of Luebeck University Hospital Schleswig-Holstein, Luebeck, Germany., Kormilez D; Institute for Medical Biometry and Statistics, University of Luebeck University Hospital Schleswig-Holstein, Luebeck, Germany., Rosenstiel P; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Schreiber S; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Aden K; Institute of Clinical Molecular Biology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.; Department of Internal Medicine I, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany., Röcken C; Department of Pathology, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.
Publikováno v:
Journal of Crohn's & colitis [J Crohns Colitis] 2023 Apr 03; Vol. 17 (3), pp. 389-395.
Autor:
Labrenz J; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Edelmann D; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Heitmann JS; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Salih HR; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany., Kopp-Schneider A; Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany., Schlenk RF; NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.; Department of Internal Medicine V and Internal Medicine VI, Heidelberg University Hospital, Heidelberg, Germany.
Publikováno v:
Pharmaceutical statistics [Pharm Stat] 2023 Mar; Vol. 22 (2), pp. 236-247. Date of Electronic Publication: 2022 Oct 25.